Ataraxia VC
San Francisco · Seed–Series A · 2 people tracked
Investment thesis
Early-stage investor specializing in companies that help people live longer and better, offering complementary expertise via two funds: delightful moments and the science of health and happiness.
Team · 2 people
from the firm's website
Mike Edelhart, who launched Ziff‑Davis properties like PC Magazine, applies editorial rigor to assess founder character and narrative clarity at inception, focusing on companies that improve emotional well‑being.
Frequently asked questions
- What stage does Ataraxia VC invest at?
- Ataraxia VC invests at the Seed, Series A stages.
- What is Ataraxia VC's typical check size?
- Ataraxia VC typically writes checks of $50K – $1M.
- What sectors does Ataraxia VC focus on?
- Ataraxia VC focuses on AgTech, Biotech, Consumer, FoodTech, Healthtech, Social.
- Where is Ataraxia VC located?
- Ataraxia VC is headquartered in San Francisco, US.
- Does Ataraxia VC lead rounds?
- Ataraxia VC typically participates in rounds rather than leading them.
Similar investors
Everywhere Ventures is an early-stage venture firm, backed by a community of founders and operators as LPs, that writes early checks (including pre-seed) into startups worldwide.
B Current Impact Investment is a Taiwan-based venture capital fund focused entirely on impact investing, supporting social innovation and entrepreneurship teams with capital and hands-on post-investment support to pursue sustainable growth.
RezVen Partners is an early- and growth-stage technology investment firm that advises, invests in, and accelerates startups, offering hands-on board-level guidance alongside capital and access to a strategic partner network.
Kibo Ventures is a Spanish venture capital firm that backs startups, having served as an early and long-term institutional investor to companies across Spain and Europe.
Lerer Hippeau is an early-stage venture capital firm that backs founders across sectors, emphasizing investing in companies before they gain wider recognition.